Recent Grants
The Center and its core facilities have been instrumental in developing public and private partnerships and have played a key role developing and submitting to federal agencies cross-disciplinary grant applications for research on nanomedicine technologies including successful renewal of the Carolina Center of Cancer Nanotechnology Excellence (CCNE) and establishment of the Carolina Cancer Nanotechnology Training Program (C-CNTP).
Kristy Ainslie, Ph.D.
- Host Targeted Therapy for Drug Resistant Salmonella and Francisella infection
5R01AI125147
NIAID, 04/22/2016 – 03/31/2021; Role: PI - Nanofiber Matrices to Improve Neural Stem Cell-Mediated Cancer Therapy
5R01NS097507
NINDS, 06/01/2016 – 05/31/2021; Role: Co-Investigator - Advancing Formulation of Sting Agonist For Universal Flu Vaccine
1R41AI140795
NIAID, Immvention Therapeutix, Inc., 06/01/2018 – 10/31/2019; Role: PI - Biomaterials to Study Tolerance Immune Induction Kinetics
1R01AI137525
NIAID, 08/14/2018 – 07/31/2023; Role: PI
Eric Michael Bachelder, Ph.D.
- Host Targeted Therapy for Drug Resistant Salmonella and Francisella infection
5R01AI125147
NIAID, 04/22/2016 – 03/31/2021; Role: Co-Investigator - Nanofiber Matrices to Improve Neural Stem Cell-Mediated Cancer Therapy
5R01NS097507
NINDS, 06/01/2016 – 05/31/2021; Role: Co-Investigator - Advancing Formulation of Sting Agonist For Universal Flu Vaccine
1R41AI140795
NIAID, Immvention Therapeutix, Inc., 06/01/2018 – 10/31/2019; Role: Co-Investigator - Biomaterials to Study Tolerance Immune Induction Kinetics
1R01AI137525
NIAID, 08/14/2018 – 07/31/2023; Role: Co-Investigator - Micro-Particle Delivery of a Potent Intracellular Adjuvant for a Universal Flu Vaccine
1R01AI141333
NIAID, 12/14/2018 – 11/30/2023; Role: PI
Edward Moreira Bahnson, Ph.D.
- Cell-Mediated Targeted Redox Intervention for the Prevention of Restenosis in the Injured Vasculature
CTSA KL2, 05/01/2017—04/30/2020; Role: PI - Molecular Imaging of Atherosclerosis in Mutant ApoE Deficient Rats
Burroughs Wellcome Fund, 06/01/2018—12/31/2019; Role: PI
Elena Batrakova, Ph.D
- Cell-Based Platform for Gene Delivery to the Brain
1R01NS102412
NINDS, 03/01/2018 – 11/30/2022; Role: PI
Soumya Benhabbour, Ph.D.
- Development and Pre-Clinical Evaluation of a Novel Polymer-Based In-Situ Forming Implant (ISFI) for Long-Acting HIV PrEP
5R01AI131430
NIAID, 03/06/2017 – 02/29/2020; Role: PI - Innovative 3D Printed Intravaginal Rings: Reengineering Multipurpose Intravaginal Rings for Prevention of HIV, STIs and Unintended Pregnancy
1R61AI136002
NIAID, 08/08/2018 – 07/31/2020; Role: PI
Yevgeny Brudno, Ph.D.
- Biomaterial-Assisted In Situ Generation of CAR-T Cells
Flash Grant
North Carolina Biotechnology Center, 04/01/2019 – 12/31/2019; Role: PI - Refillable Therapeutic Depots for Treatment of Brain Disease
Junior Faculty Development Award
UNC Chapel Hill, 01/01/2019 – 01/31/2020; Role: PI - Local Immunotherapy Made Possible by Click-Enabled Refillable Therapeutic Depots
Faculty Research and Professional Development Program
NC State University, 09/01/2018 – 09/30/2019; Role: PI
Paul Dayton, M.D.
- Ultrasound Molecular Imaging to Assess Therapeutic Response
5R01CA195051
NCI, University of Colorado, 04/13/2015 – 03/31/2020; Role: PI - The Application of Enhanced Cavitation to Enable DNA and Chromatin Extraction from Archived Tissues
1R33CA206939
NCI, 07/01/2017 – 06/30/2020; Role: PI - High Frame Rate 3-D Super Resolution Ultrasound Microvascular Imaging
1R01CA220681
NCI, 08/10/2017 – 07/31/2022; Role: PI - An Academic Industrial Partnership for the Development of High Frame-Rate Transcranial Super Resolution Ultrasound Imaging
5R01EB025149
NIBIB, 09/30/2017 – 07/31/2020; Role: PI - Treating Tumoral Hypoxia via Ultrasound-Guided Oxygen Release for Improving Radiation Therapy
1R01CA232148
NCI, 06/01/2018 – 05/31/2023; Role PI - Acoustic Angiography Using Dual-Frequency and Ultrawideband CMUT Arrays
1R01EB026897
NIBIB, NC State University, 07/01/2018 – 03/31/2022; Role: PI - Towards Commercialization of Cavitation-Enhancing Nanodroplets for DNA Sample Fragmentation in NGS Applications
1R43CA232902
NCI, Triangle Biotechnology, Inc., 07/05/2018 – 06/20/2019; Role: PI
Zongchao Han, M.D., Ph.D.
- Targeting Retinitis Pigmentosa Using Nanoparticle-Mediated Delivery of Genomic DNA
1R01EY026564
NEI, 04/01/2016 – 03/31/2021; Role: PI
Shawn D. Hingtgen, Ph.D.
- Nanofiber Matrices to Improve Neural Stem Cell-Mediated Cancer Therapy
5R01NS097507
NINDS, 06/01/2016 – 05/31/2021; Role: PI - 3D Printing of Fibrous Tissue Engineered Medical Products: A New Paradigm for Tissue Biofabrication and Therapeutics
NCSU GRIP, 02/01/2017 – 1/31/2020; Role: PI - Engineering Stem Cell Therapies to Understand and Overcome Glioblastoma Adaption
1R01NS099368
NINDS, 09/26/2017 – 06/30/2022; Role: PI - Native and Bioprinted 3D Tissue Array Platform for Predicting Cancer Metastasis and Drug Response
Eshelman Institute for Innovation, 06/01/2018—05/31/2020; Role: PI
Leaf Huang, Ph.D.
- Nano Approaches to Modulate Host Cell Response for Cancer Therapy
1U54CA198999
NCI, 09/01/2015 – 07/31/2020; Role: PI - Developmental Program
1U54CA198999
NCI, 09/01/2015 – 07/31/2020; Role: PI - Administrative Core
1U54CA198999
NCI, 09/01/2015 – 07/31/2020; Role: PI - Project 1: Nanotherapies for Vemurafenib Resistant Melanoma
1U54CA198999
NCI, 09/01/2015 – 07/31/2020; Role: PI - Targeting Tumor Associated Fibroblasts to Enhance Therapy
Eshelman Institute for Innovation, 06/01/2019 – 05/31/2021; Role: PI
Michael Jay, Ph.D.
- Non-Opiate Topical Formulations for Treating Pain Associated with Molar Extractions
1R41DE028208
NCI, Arcato Laboratories, 09/18/2018 – 09/17/2019; Role: PI
Alexander Kabanov, Ph.D., Dr. Sci.
- PEGylated Liposomal Doxorubicin and Pluronic Combination for Cancer Therapy
5R01CA184088
NCI, 01/01/2015 – 12/31/2019; Role: PI - Carolina Cancer Nanotechnology Training Program (C-CNTP)
5T32CA196589
NCI, 07/01/2015 – 06/30/2020; Role: Director - Targeted Core Shell Nanogels for Triple Negative Breast Cancer
5U01CA198910
NCI, 08/14/2015- 07/31/2020; Role: PI - Project 4: High Capacity Polymeric Micelle Therapeutics for Lung Cancer
5U54CA198999
NCI, 09/01/2015 – 07/31/2020; Role: PI - Systemic Targeting of Mononuclear Phagocytes for Parkinson’s Disease Gene Therapy
Eshelman Institute for Innovation, 06/01/2017 – 05/31/2020; Role: PI - Targeted Magneto-Mechanic Nanotherapeutics for Cancer
1R21CA220148
NCI, 08/1/2017 – 07/31/2020; Role: PI - Nanoparticle Delivery of Cas9 and Therapeutic gRNAs to the Brain
Eshelman Institute for Innovation, 06/01/2018 – 05/31/2020; Role: PI - Targeting of Inflamed Monocytes for Gene Therapy of Cancer
Eshelman Institute for Innovation, 06/01/2019 – 05/31/2020; Role: PI - Targeting Tumor Associated Fibroblasts to Enhance Therapy
Eshelman Institute for Innovation, 06/01/2019 – 05/31/2021; Role: Co-Investigator
Melina Kibbe, M.D.
- Bioengineering Catalytically Active Grafts for Vascular Surgery
5I01BX002282
VA, Durham VA Medical Center, 10/01/2014 – 09/30/2019 - Development of a Targeted Intravascular Therapy to Stop Non-Compressible Torso Hemorrhage
Air Force Research Laboratory, University of Cincinnati, 10/24/2016 – 10/23/2019; Role: PI - Targeted, Niche-Responsive Peptide Amphiphile Nanofibers as Injectable Drug Delivery Vehicles to Treat Atherosclerosis
American Heart Association, 07/01/2018 – 06/30/2020; Role: PI - A Novel Endovascular Approach to Remove Atherosclerotic Plaque Lesions In Situ
1R01HL129156
NHLBI, 01/01/2019 – 12/31/2022; Role: PI
Sam Lai, Ph.D.
- Enhancing AAV Gene Therapy via Bispecific Fusion Proteins that Block anti-AAV Antibodies while Conferring Active Targeting
NCBC, 11/01/2017 – 10/31/2019; Role: PI - Overcoming anti-PEG Immunity to Restore Prolonged Circulation and Efficacy of PEGylated Therapeutics
1R01HL141934
NHLBI, 05/10/2018 – 04/30/2022; Role: PI - In Vivo Engineering of T-cells for CAR-T-based Therapy
Eshelman Institute for Innovation, 06/01/2018—05/31/2020; Role: PI - An Integrated Neural Network Analysis and Video Microscopy Platform for Fully Automated Particle Tracking
1R41GM130202
NIGMS, AI Tracking Solutions, 09/13/2018 – 09/12/2020; Role: PI
Rihe Liu, Ph.D.
- Targeted Core Shell Nanogels for Triple Negative Breast Cancer
1U01CA198910
NCI, 08/14/2015 – 07/31/2020; Role: PI - Nano Approaches to Modulate Host Cell Response for Cancer Therapy
1U54CA198999
NCI, 09/01/2015 – 07/31/2020; Role: Co-Investigator - Inhibition Of GTPases and G Proteins to Treat Human Disease
5R01GM120291
NIGMS, 09/15/2016 – 07/31/2020; Role: PI - Nanoscintillator-Based X-ray Sensitizers to Enable Efficient Non-Small Cell Lung Cancer Treatment with X-ray Irradiation
5R01EB022596
NIBIB, University of Georgia, 03/15/2017 – 01/31/2021; Role: Co-Investigator - A Wholly Protein-Based Self-Assembly Nanoplatform for Tunable Cancer Immunotherapy
Eshelman Institute for Innovation, 06/01/2018—05/31/2020; Role: PI
Chad Pecot, M.D.
- Tumor Angiogenesis Regulation by the miR-200 Family
MRSG-14-222-01
American Cancer Society, 01/01/2015 –12/31/2019; Role: PI - Targeting Lung Squamous Metastasis with CCR2 Inhibitors
Free to Breath, 02/14/2017 – 12/31/2019; Role: PI - HDAC11 Promotes Breast Cancer Metastasis via the Lymphatic Route
Susan G. Komen for the Cure; 08/07/2017 – 08/06/2020; Role: PI - Immune Regulation of Lung Squamous Metastasis
1R01CA215075
NCI, 09/21/2017 – 08/31/2022; Role: PI
Marina Sokolsky, Ph.D.
- Targeted Magneto-Mechanic Nanotherapeutics for Cancer
1R21CA220148
NCI, 8/1/2017 – 7/31/2020; Role: Co-Investigator - BCL-xL-regulated Apoptosis in Cerebellar Development and Medulloblastoma Treatment
1R01NS102627
NINDS, 06/01/2018 – 04/30/2023; Role: Co-Investigator
Alexander Tropsha, Ph.D.
- Nano Approaches to Modulate Host Cell Response for Cancer Therapy
1U54CA198999
NCI, 09/01/2015 – 07/31/2020; Role: Co-Investigator - Integrating Cheminformatics and Molecular Simulations for Virtual Drug Screening
5R01GM114015
NIGMS, 08/15/2016 – 05/31/2020; Role: Co-Investigator - Drug Repurposing for Cancer Therapy: From Man to Molecules to Man
5U01CA207160
NCI, 09/01/2016 – 08/31/2019; Role: PI - Carolina Biomedical Data Translator Technical Feasibility Assessment and Architecture Design
1OT3TR002020
NCATS, 09/24/2016 – 12/31/2019; Role: PI - Chemoenzymatic Synthesis, Mode of Action and Evolution of Natural Product-Based Macrocycles
1R35GM125005
NIGMS, 09/05/2017 – 08/31/2022; Role: Co-Investigator - Carolina Biomedical Data Translator Technical Feasibility Assessment of Reasoning Tool
3OT2TR002514
NCATS, 01/05/2018 – 01/04/2020; Role: PI - Dual Mechanism Thiopeptide Analogs for TB Drug Development
1R21AI138058
NIAID, 05/10/2018 – 04/30/2020; Role: Co-Investigator - Drug Repurposing for Alzheimer’s Disease Using both Observational and Chemical Genomics Data
1R56AG059428
NIA, 08/15/2018 – 07/31/2020; Role: PI
Nick Tsihlis, Ph.D.
- Development of a Targeted Intravascular Therapy to Stop Non-Compressible Torso Hemorrhage
Air Force Research Laboratory, University of Cincinnati, 10/24/2016—10/23/2019; Role: Co-Investigator
Andrew Wang, M.D.
- Carolina Cancer Nanotechnology Training Program (C-CNTP)
5T32CA196589
NCI, 7/01/2015 – 6/30/2020; Role: Co-Director - Targeted Core Shell Nanogels for Triple Negative Breast Cancer
5U01CA198910
NCI, 08/14/2015 – 07/31/2020; Role: Co-Investigator - Project 3: Combining Radiotherapy and Nanotechnology for Immunotherapy
1U54CA198999
NCI, 09/01/2015 – 07/31/2020; Role: PI - Automatic Pelvic Organ Delineation in Prostate Cancer Treatment
5R01CA206100
NCI, 09/01/2016 – 07/31/2021; Role: Co-Investigator - Nanoscintillator-Based X-ray Sensitizers to Enable Efficient Non-Small Cell Lung Cancer Treatment with X-ray Irradiation
5R01EB022596
NIBIB, University of Georgia, 03/15/2017 – 01/31/2021; Role: Co-Investigator
William Zamboni, Pharm.D., Ph.D.
- Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer
5UM1CA186704
NCI, Duke University, 04/04/2014 – 02/29/2020; Role: Co-Investigator - Liposomal Doxorubicin and Pluronic Combination for Cancer Therapy
5R01CA184088
NCI, 01/01/2015 – 12/31/2019; Role: PI - Targeted Core Shell Nanogels for Triple Negative Breast Cancer
5U01CA198910
NCI, 08/14/2015 – 07/31/2020; Role: Co-Investigator - Project 4: High Capacity Polymeric Micelle Therapeutics for Lung Cancer
5U54CA198999
NCI, 09/01/2015 – 07/31/2020; Role: Co-Investigator - Overcoming Anti-PEG Immunity to Restore Prolonged Circulation and Efficacy of PEGylated Therapeutics
1R01HL141934
NHLBI, 05/10/2018 – 04/30/2022; Role: PI